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Summary
Over the last few years, there have been many changes
in the management of patients with follicular lymphoma,
resulting in improvements in progression-free survival and
quality of life. In addition to established regimens such
as radiotherapy and immunochemotherapy, new treatment
options are on the horizon. Furthermore, even the use
of established chemotherapy agents has evolved, with
new combinations moving to the forefront of the current
treatment strategy. Nevertheless, there remains an unmet
need for patients who have early relapses, those who are
not responsive to anti-CD20 treatment regimens and for
those in whom minimal residual disease persists even af-
ter immunochemotherapy. This review provides a summa-
ry of current developments in the diagnosis, treatment and
management of follicular lymphoma, focusing on the clini-
cal issues from a Swiss perspective.
Keywords: follicular lymphoma, first-line treatment, main-
tenance treatment, relapse/refractory disease, follow-up
Introduction
Histogenetically, follicular lymphoma arises from germi-
nal centre B cells. As a low-grade tumour, it is the most
commonly occurring subtype among indolent B cell lym-
phomas in the Western world [1, 2]. Follicular lymphoma
is characterised by a relapsing and remitting disease course
that may undergo transition to a more aggressive disease.
In the past few years, new treatment regimens have made
an impact on the management of follicular lymphoma, re-
sulting in more favourable clinical outcomes. The median
overall survival has improved dramatically and can now
reach 10 to 12 years or more [3, 4]. Immunochemothera-
py is currently the standard of care for patients with ad-
vanced-stage follicular lymphoma in need of treatment [5].
ABBREVIATIONS
BNLI British National Lymphoma Investigation
BR bendamustine-rituximab
CI confidence interval
CT computed tomography
CVP cyclophosphamide, vincristine and prednisone
DLBCL diffuse large B cell lymphoma
ESMO European Society for Medical Oncology
FACS fluorescence-activated cell sorting
18F-FDG 18F-fluorodeoxyglucose
FISH fluorescence in situ hybridisation
FLIPI Follicular Lymphoma International Prognostic Index
GB obinutuzumab plus bendamustine
G-CHOP obinutuzumab plus cyclophosphamide, hydroxy-
daunorubicin (doxorubicin), Oncovin (vincristine), and
prednisone
G-FC obinutuzumab plus fludarabine/cyclophosphamide
HBV hepatitis B virus
HCV hepatitis C virus
HPF high-power field
NHL non-Hodgkin’s lymphoma
HR hazard ratio
PET positron emission tomography
PCR polymerase chain reaction
R-CHOP rituximab plus cyclophosphamide, hydroxydaunorubicin
(doxorubicin), Oncovin (vincristine) and prednisone
R-CVP rituximab plus cyclophosphamide, vincristine and pred-
nisone
R-FM rituximab-fludarabine plus mitoxantrone
SAKK Swiss Group for Clinical Cancer Research
StiL the German Study Group Indolent Lymphoma
WHO World Health Organization
Correspondence:
Professor Dr. med.
Christoph Renner,,
Onkozentrum Hirslanden,,
Witellikerstr. 40,, CH-8038
Zürich,, Christoph.Ren-
ner[at]hirslanden.ch
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 1 of 12
Chemotherapy-free treatment with anti-CD20 antibodies
(such as rituximab) is an option for those with a low dis-
ease burden. Nevertheless, the majority of patients will ex-
perience relapse and require several lines of therapy. There
is still the need for effective regimens that achieve disease
control with minimal treatment-related toxicity.
This review follows our 2011 publication on the treatment
and management of follicular lymphoma [6] and represents
an update on the key issues encountered in clinical practice
from a Swiss perspective.
Pathology and staging
Histologically, follicular lymphoma is diagnosed accord-
ing to the criteria of the 4th World Health Organization
(WHO) classification issued in 2008 and updated in 2017
[7, 8]. Follicular lymphoma is defined as a neoplasm com-
posed of germinal centre B cells, namely centroblasts and
centrocytes, exhibiting, in most cases at least, a partly fol-
licular growth pattern [8] (fig. 1). Grading of follicular
lymphoma is mandatory and is based on the count of cen-
troblasts per high-power field (HPF); in general, tumours
with more numerous centroblasts show more aggressive
clinical behaviour [8]. Grade 1 (0–5 centroblasts per HPF)
and grade 2 (6–15 centroblasts per HPF) tumours with
similar clinical characteristics are considered to be of low
grade. Grade 3 tumours are considered to be high-grade,
and are further divided into 3a and 3b neoplasms; both ex-
hibit >15 centroblasts per HPF but confluent sheets and
strands of centroblasts are present in grade 3b neoplasms
[9]. Although still under debate, grade 3b follicular lym-
phoma may be biologically distinct from other follicular
lymphomas, with a more aggressive course and with vary-
ing molecular and genetic features (table 1) [11], including
the absence of the t(14;18)(q32;q21) chromosomal
translocation, down-regulation of CD10 protein and over-
expression of mutated melanoma-associated antigen 1
(MUM-1) protein [12]. Another issue is how to interpret a
coexisting tumour component of diffuse large B cell lym-
phoma (DLBCL) next to follicular lymphoma of any grade
of malignancy, recognised by the valid WHO classifica-
tion as an additional second tumour [10]. This point is key
for distinguishing between de novo DLBCL and transfor-
mation of initial follicular lymphoma, which occurs in ap-
proximately 30 to 40% of follicular lymphoma patients
[13]. For the clinician, the distinction between grade 3a
and 3b follicular lymphoma is crucial and determines prog-
nosis and therapeutic strategy. Clinically, most patients
initially present with asymptomatic peripheral lym-
phadenopathy, affecting the cervical, axillary, femoral and
inguinal regions [14, 15]. Although lymph nodes are most
commonly primarily involved, the disease may also origi-
nate at extranodal sites. The WHO in particular recognises
(1) in situ follicular neoplasia, (2) duodenal-type follicular
lymphoma, (3) testicular follicular lymphoma and (4) dif-
fuse follicular lymphoma as four distinct variants, and fur-
thermore classifies cutaneous follicle centre lymphomas
and paediatric-type follicular lymphoma as two separate
entities [8].
Diagnosis
The 2016 European Society for Medical Oncology (ES-
MO) guidelines provide a summary for the diagnosis of
follicular lymphoma [5]. The majority of follicular lym-
phomas are diagnosed by bioptic lymph node examination;
fine-needle aspiration does not provide adequate material
for tumour grading. The same is true for trephine biopsies
that have to be performed for staging purposes, as follic-
ular lymphoma involves bone marrow in about 60 to 70%
of patients [16]. For the definition of bulky disease, which
has varied over time, we propose a cut-off of >7 cm diam-
eter, in keeping with the ESMO guidelines [5]. The biolog-
ical heterogeneity and disseminated presentation of follic-
ular lymphoma makes it difficult to select a site for biopsy.
The factors that should be taken into account when choos-
ing a biopsy site are accessibility for surgical removal and
Figure 1: Enlarged cervical lymph node (4 cm in diameter) of a 64-year-old male patient harbouring follicular lymphoma (FL) of varying histo-
logical grades, including transformation into a diffuse large B-cell lymphoma (DLBCL).
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the diagnostic relevance. A selection based purely on size
of the lymph node should be avoided, owing to the possi-
bility of necrosis within large lymph nodes.
In Switzerland, a common practice is to use contrast-en-
hanced positron emission tomography / computed tomog-
raphy (PET-CT) to identify the most suitable lymph node
for biopsy [17]. Although PET-CT is not yet routinely used
for staging at diagnosis, it has been shown that follicular
lymphoma is avid for 18F-FDG (18F-fluorodeoxyglucose)
and that over 90% of patients are PET-CT positive at ini-
tial presentation [18]. For patients with early stage follic-
ular lymphoma who are scheduled for localised radiation,
PET-CT can be used to map out the area for involved-field
radiation therapy and also to exclude the presence of distal
sites of disease [19]. The latest ESMO guidelines state that
fluorescence-activated cell sorting (FACS) analysis is an
optional procedure for diagnostic work-up [5]; we suggest
that if access to FACS is available, FACS analysis on bone
marrow aspirates should be done to judge on bone marrow
involvement [20]. Of note, trephine biopsy plus immuno-
histochemistry may be more sensitive than bone marrow
aspirates plus FACS to detect bone marrow involvement in
follicular lymphoma [21].
The use of polymerase chain reaction (PCR) tests for de-
tecting B cell clonality in follicular lymphoma is associat-
ed with a high rate of false negatives, due to ongoing so-
matic immunoglobulin variable region heavy chain (IgVH)
hypermutations [22]. In addition to morphological and im-
munohistochemical studies, fluorescence in situ hybridi-
sation (FISH) is the preferred method to detect the
t(14;18)(q32;q21) chromosomal translocation, which is
most specifically found in follicular lymphoma [23, 24].
FISH analysis may have a great differential diagnostic im-
pact, separating follicular lymphoma from reactive follic-
ular hyperplasia and from lymphomas other than follicular
lymphoma.
Routine testing for hepatitis B surface antigen and hepatitis
B core antibody at baseline and before therapy is strongly
recommended for all patients who will undergo immuno-
suppressive therapy, to mitigate the risk of hepatitis B virus
(HBV) reactivation [25]. If positive, viral load assessment
by measuring HBV DNA should be performed and anti-
viral treatment initiated. HBV vaccination may be consid-
ered for patients who are HBV-negative and not in imme-
diate need of treatment.
Prognosis
The Follicular Lymphoma International Prognostic Index
(FLIPI) [26] is routinely used as a general prognostic tool.
The FLIPI was developed before the rituximab era. The
five main prognostic factors are the number of nodal sites
(≤ or >4), lactate dehydrogenase (normal vs elevated), age
(≤ or >60 years), stage (I, II vs III, IV), and haemoglobin
(normal vs <120 g/L). The FLIPI-2 includes age >60 years,
elevated β2-microglobulin levels, haemoglobin <120 g/l,
bone marrow involvement, and lymph node diameter >6
cm as independent risk factors for progression-free sur-
vival in the era of rituximab chemotherapy. The FLIPI-2
so far has not gained acceptance and is still investigational.
The recent m7-FLIPI index integrates the mutation status
of seven clinically relevant genes together with the FLIPI
and Eastern Cooperative Oncology Group (ECOG) perfor-
mance status, in order to identify the subset of follicular
lymphoma patients who are at greatest risk of treatment
failure [27]. None of these scoring indexes provide guid-
ance on when to initiate therapy.
First-line treatment
The trigger point for starting treatment remains a difficult
question. A key driver for beginning treatment is the pres-
ence of symptomatic disease. The criteria outlined by the
Swiss Group for Clinical Cancer Research (SAKK) for
starting treatment includes the presence of at least one
of the following: B symptoms; symptomatically enlarged
lymph nodes or spleen; clinically significant progression
of lymphadenopathy, splenomegaly or other follicular lym-
phoma lesions; involvement of at least three nodal sites
larger than 3 cm, presence of bulky disease, haemoglobin
<100 g/l, and platelets <100 × 109/l [28]. According to the
British National Lymphoma Investigation (BNLI), bone le-
sions may also be regarded as a trigger for initiating treat-
ment. The SAKK criteria for initiating treatment are sum-
marised in table 2, alongside the criteria for the Groupe
d’Etude des Lymphomes Folliculaires and the BNLI
groups for comparison. Symptomatic bone marrow in-
volvement is also a criterion for beginning treatment.
However, the decision to start treatment often has to be
individualised and is reached upon mutual agreement be-
tween the patient and clinician.
Around 10% of low-grade follicular lymphomas are diag-
nosed in early stage I or II [31]. Radiation therapy is the
treatment of choice for these patients, with the possibility
of long-lasting remissions and curative potential [32]. The
treatment volume has evolved over the past decades from
the earlier extended-field to involved-field and, more re-
cently, to involved-site radiotherapy. Involved-site radio-
therapy treats the affected nodes with a clinical target vol-
ume margin of a few centimetres. The reduced toxicity
linked to involved-site radiotherapy comes at the cost of
a potentially higher recurrence rate in untreated adjacent
areas. Nowadays, primary radiation therapy is given at a
dose of 24 Gy, which is significantly lower than the doses
delivered in the past (30–40 Gy). This development is the
result of a randomised trial comparing 24 Gy to 40 Gy in
Table 1: Features that distinguish grade 3b follicular lymphoma from grades 1–3a [9, 10].
Grades 1–3a Grade 3b
WHO grading scheme Grades 1–2 ≤15 centroblasts per high-power field*
Grade 3a >15 centroblasts per high-power field
>15 centroblasts per high-power field
Presence of solid sheets of centroblasts
Genotype t(14;18)(q32;q21); BCL2-IGH in 90% of cases t(14;18)(q32;q21); BCL2-IGH in 50% of cases
t(3;14)(q27;q32);BCL6-IGH in 10% of cases
Immunohistochemistry Expression of CD10 Down-regulation of CD10
Expression of MUM1
Clinical behaviour Indolent Aggressive, resembling DLBCL
DLBCL = diffuse large B cell lymphoma; MUM-1 = mutated melanoma-associated antigen; WHO = world Health Organization * high-power field defined as 0.159 mm2
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indolent lymphomas, demonstrating similar efficacy with
both doses [33]. Reports from patient cohorts that were
treated with low-dose radiotherapy of 2 × 2 Gy, mostly
for palliation of advanced disease, showed promising re-
sults [34, 35]. Therefore, a randomised trial was carried out
to compare 2 × 2 Gy with the standard dose of 24 Gy in
follicular lymphoma [36]. Preliminary results demonstrat-
ed a significantly higher rate of progression in the low-
dose group, so the 4 Gy dose should not be adopted for
treatment with curative intent. Importantly, toxicity in the
24 Gy group was low, with <3% grade III acute reactions,
demonstrating the safety of modern schedules of radiation
therapy with limited treatment volumes and radiation dos-
es. However, the preferred 24 Gy dose is not accepted by
all groups and some use a minimum of 30 Gy [37].
It should be noted that most of the relapses in patients with
early-stage follicular lymphoma occur outside the irradiat-
ed fields [38]. Indeed, an important finding from the Lym-
phomaCare study was that rigorously staged patients had
superior progression-free survival compared with patients
who had not undergone a rigorous staging process [31].
In a retrospective study conducted in 310 patients with lo-
calised follicular lymphoma, excellent outcomes were ob-
tained after radiotherapy in patients who were PET-CT
staged (5-year overall survival: 95.8%) [39]. This reiterates
the importance of accurate staging using PET-CT prior to
radiation therapy, in order to define the areas to be irradiat-
ed and to rule out occult disease [38, 40].
Besides radiotherapy alone, the combination with ritux-
imab for early stage follicular lymphoma has been tested
in the MIR trial [41, 42]. Preliminary data show an ex-
cellent progression-free survival of almost 80% at 5 years
after treatment [42]. A comparison of various first-line
treatment strategies in 471 patients with stage I follicular
lymphoma who participated in the LymphomaCare study
showed that the different approaches resulted in similar
outcomes [31]. Recent data from a randomised controlled
trial in 150 patients with stage I–II follicular lymphoma in-
dicated that treatment with six cycles of CVP (cyclophos-
phamide, vincristine and prednisone) or rituximab‐CVP
after involved-field radiotherapy significantly improved
progression-free survival compared with radiotherapy
alone (10-year progression-free survival 58 vs 41%, re-
spectively) [43]. This suggests that systemic therapy may
prevent progression outside of the radiation fields. Howev-
er, it is not yet clear if the combination of radiotherapy plus
rituximab-based systemic therapy will become standard of
care in the future.
Watchful waiting remains an acceptable approach in se-
lected patients in the rituximab era, with no detrimental ef-
fects on overall survival [44–46]. However, better indices
are needed to identify patients who may benefit from early
intervention. There is also no conclusive data on whether
watchful waiting affects the incidence of transformation of
follicular lymphoma. For elderly patients and those with
poor performance status, watchful waiting can be consid-
ered in selected cases [47].
For patients with symptomatic stage I–II disease without
the option to undergo radiotherapy and those with ad-
vanced disease (stage III–IV), the treatment approach is
similar. Current standard of care for first-line treatment
of advanced follicular lymphoma consists of im-
munochemotherapy with the anti-CD20 monoclonal an-
tibody rituximab (MabThera®/Rituxan®) in combination
with a chemotherapy component [5]. Although the ESMO
guidelines place equal emphasis on the use of bendamus-
tine and CHOP (cyclophosphamide, doxorubicin, vin-
cristine and prednisone), bendamustine has increasingly
been used combined with rituximab [15]. A randomised,
multicentre phase III trial by the Study group Indolent
Lymphoma (StiL) compared rituximab-CHOP (R-CHOP)
with bendamustine-rituximab in 549 treatment-naïve pa-
tients with indolent and mantle cell lymphoma. In the sub-
group of patients with follicular lymphoma, median pro-
gression-free survival was significantly better in the
bendamustine-rituximab group compared with R-CHOP
(median progression-free survival not reached vs 40.9
months; p = 0.007). Furthermore, the bendamustine-ritux-
imab regimen had fewer adverse effects [48]. Results from
the BRIGHT study indicated that bendamustine-rituximab
was non-inferior to R-CHOP or R-CVP in terms of com-
plete response (31 vs 25%, respectively; p = 0.0225) and
overall response (97 and 91%, respectively; p = 0.0102)
in 447 patients with indolent non-Hodgkin’s lymphoma
Table 2: Comparison of criteria for starting treatment in follicular lymphoma patients.
Group Criteria
Swiss Group for Clinical Cancer Research (SAKK)
[28]
• Presence of B symptoms
• Symptomatic enlarged lymph nodes or spleen
• Clinically significant progression of lymphadenopathy, splenomegaly or other FL lesions (50% increase in size over a
period of at least 6 months)
• At least 3 nodal sites involved (>3 cm)
• Presence of bulky disease (>7 cm)
• Haemoglobin level <100 g/l
• Platelet level <100 × 109/l (due to bone marrow infiltration or splenomegaly)
British National Lymphoma Investigation (BNLI) [29] • Presence of pruritus or B symptoms
• Rapid disease progression during the past 3 months
• Life-threatening organ involvement
• Significant bone marrow infiltration resulting in bone marrow depression (defined as a haemoglobin level <100 g/l, white
cell count <3.0 × 109/l, or platelet count <100 × 109/l in the absence of other causes)
• Localised bone lesions
• Renal infiltration
• Macroscopic liver involvement
Groupe d’Etude des Lymphomes Folliculaires
(GELF) [30]
• Largest nodal (or extranodal) size >7 cm
• At least 3 nodal sites of >3 cm
• Presence of systemic symptoms
• Presence of serous effusion
• Substantial enlargement of the spleen
• Risk of vital organ compression
• Presence of leukaemia or blood cytopenias
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(NHL) or mantle cell lymphoma [49]. The safety findings
of the BRIGHT study differed from the StiL study in that
bendamustine-rituximab was found to have a distinct safe-
ty profile compared with R-CHOP or R-CVP, but the over-
all tolerability of the bendamustine-rituximab regimen was
favourable in this clinical setting [49]. A recent 5-year up-
date of the BRIGHT study identified a higher risk of sec-
ondary cancers (mainly skin cancers) in the bendamustine-
rituximab arm and it was speculated that this could have
been due to rituximab maintenance (which was used in
43% of the patients) [50]. It should be kept in mind that
there is less long-term follow-up data for bendamustine-rit-
uximab compared with R-CHOP; this is especially relevant
when weighing the treatment options for younger patients.
Although the findings from the StiL and BRIGHT studies
point towards bendamustine-rituximab as the treatment of
choice for follicular lymphoma patients with grade 1 and
2 disease, the optimal treatment for patients with grade 3a
disease remains unclear: these patients were not includ-
ed in either study. The FOLLO5 trial assessed R-CHOP,
R-CVP and rituximab, fludarabine and mitoxantrone (R-
FM) as front-line treatment in 534 patients with advanced-
stage follicular lymphoma [51]. The overall response rates
were 88, 93 and 91% for R-CVP, R-CHOP and R-FM, re-
spectively (p = 0.247). The 3-year progression-free sur-
vival rates were 52, 68 and 63% (p = 0.011), respectively,
and 3-year overall survival was 95% for the whole series.
The authors concluded that R-CHOP and R-FM were su-
perior to R-CVP in terms of 3-year time to treatment fail-
ure and progression-free survival, but R-CHOP had a more
favourable risk-benefit profile [51]. These findings were
recently confirmed, with 8-year progression-free survival
rates of 57 and 59% for R-CHOP and R-FM, compared
with 46% for R-CVP [52].
In Switzerland, bendamustine-rituximab is widely used as
a front-line treatment option in patients with grade 3a fol-
licular lymphoma, although R-CHOP is also used in
Switzerland [53]. Many clinicians regard R-CHOP as
overtreatment for low-grade follicular lymphoma, but
whether grade 3a is considered high- or low-grade disease
is still a matter of debate [54]. The results from the StiL
and BRIGHT trials, alongside the findings of several other
studies with bendamustine-rituximab [55, 56], indicate that
the bendamustine-rituximab combination may be prefer-
able to R-CHOP or R-CVP for the front-line treatment of
follicular lymphoma patients with low-grade disease who
need therapy. The findings from the FOLLO5 study indi-
cate that R-CHOP still holds a place in the first-line treat-
ment of patients with high-risk characteristics, including
those with evidence of bone marrow involvement and high
levels of β2-microglobulin [57].
For patients who are in need of treatment but who may not
be able to tolerate chemotherapy, or for those with a low
disease burden, rituximab monotherapy provides a safe
and effective first-line treatment option, with the potential
for lasting molecular responses [58, 59]. The SAKK test-
ed rituximab monotherapy in chemotherapy-naïve and pre-
treated follicular lymphoma patients, resulting in overall
response rates of 67 and 46%, respectively [60]. Data from
the SAKK 35/98 trial indicated that the independent fac-
tors predictive of response to treatment with single-agent
rituximab were: low disease bulk (<5 cm), follicular his-
tology, normal haemoglobin levels and low lymphocyte
counts [61]. At long-term follow-up, 35% of patients did
not show disease progression after 8 years [28]. This num-
ber was 45% in the subgroup of previously untreated pa-
tients who responded to rituximab induction and who were
given prolonged rituximab maintenance [28]. Despite the
fact that single-agent rituximab is widely accepted both in
Switzerland and internationally [28], and is recommend-
ed in the latest ESMO guidelines [5], rituximab monother-
apy is still not on the Swiss Specialties List and this is
considered off-label use in Switzerland. Within the SAKK,
the aim is to develop further regimens using anti-CD20
antibodies as a backbone, in combination with new mol-
ecules such as immunomodulatory drugs (e.g., lenalido-
mide; SAKK 35/10 trial), or Bruton’s tyrosine kinase in-
hibitors (ibrutinib; SAKK 35/14 trial), as well as the
BCL-2 inhibitor venetoclax (SAKK 35/15 trial). Further
details on the ongoing SAKK trials can be found on
www.sakk.ch/en/sakk-provides/our-trials/. The combina-
tion of lenalidomide with rituximab (also known as R2)
has shown good potential for the treatment of indolent
lymphomas, including follicular lymphoma [62]. In previ-
ously untreated patients with indolent NHL, lenalidomide-
rituximab treatment showed good overall response rates
(75–96%) and complete response or unconfirmed complete
response rates between 36 and 71% [63]. However, a re-
cent phase III trial (RELEVANCE) did not show improved
complete response / unconfirmed complete response or
progression-free survival when comparing lenalidomide-
rituximab with standard-of-care rituximab plus chemother-
apy in previously untreated follicular lymphoma patients
[64]. Other groups are studying rituximab-ibrutinib in the
front-line setting [65].
Recently, Swiss regulatory authorities have approved an
alternative anti-CD20 monoclonal antibody (obinutuzum-
ab, Gazyvaro®) plus chemotherapy followed by obinu-
tuzumab maintenance for first-line follicular lymphoma
patients. The GALLIUM study compared the efficacy and
safety of obinutuzumab-based with rituximab-based front-
line regimens head-to-head in 1202 treatment-naïve fol-
licular lymphoma patients with grade 1-3a disease [66].
Responders received either obinutuzumab or rituximab
maintenance. Results from pre-planned interim analyses
showed that obinutuzumab-based regimens resulted in bet-
ter progression-free survival. After a median follow-up of
34.5 months, there was a 34% reduction in the risk of dis-
ease progression or death with obinutuzumab-based induc-
tion regimens and maintenance. Three-year progression-
free survival rates in the obinutuzumab and rituximab arms
were 80 and 73.3%, respectively (hazard ratio [HR] 0.66,
95% confidence interval [CI] 0.51–0.85; p = 0.001); over-
all survival rates were similar in both arms. Unexpected-
ly, there was a higher incidence of toxicities in patients
on bendamustine in both arms, notably infections and sec-
ond neoplasms [66]. Although the study demonstrated a
progression-free survival advantage with the use of obinu-
tuzumab, the higher level of toxicity in the bendamustine
arms needs to be better understood before these treatment
regimens can be routinely used in the front-line setting. A
summary of first-line treatment is shown in figure 2.
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Maintenance therapy
Despite the high efficacy of initial treatment regimens, the
majority of patients with follicular lymphoma will experi-
ence relapse. The goal of maintenance therapy is to extend
the duration of remission obtained with first-line treatment;
thus, maintenance is only used for patients who respond to
first-line therapy. As a result of its consistent efficacy pro-
file and good tolerability, rituximab has been evaluated in
several larger trials as maintenance therapy, leading to con-
troversial results.
The RESORT study focused on the question of whether
rituximab maintenance prolongs response duration, com-
pared with rituximab treatment at the time of disease pro-
gression, in 408 untreated follicular lymphoma patients
with a low tumour burden [67]. Following rituximab in-
duction therapy, responders were randomised to rituximab
maintenance or retreatment at disease progression until
treatment failure. At a median follow-up of 4.5 years, the
estimated median time to treatment failure was 4.3 versus
3.9 years, respectively (p = 0.54). Better results were seen
for the maintenance arm in terms of 3-year freedom from
cytotoxic therapy (95% of patients in the maintenance arm
vs 84% in the retreatment arm; p = 0.03). However, these
benefits must be weighed against the higher amount of rit-
uximab usage in the maintenance arm. The overall sur-
vival in both arms was 94% at 5 years, and both treatment
regimens were well tolerated. The authors concluded that
retreatment at disease progression when single-agent rit-
uximab is used as front-line therapy in patients with low
tumour burden is preferable to maintenance rituximab.
Several other studies have evaluated the use of mainte-
nance rituximab in the setting of front-line treatment or
relapsed disease [60, 68–71]. The SAKK 35/98 trial in-
cluded newly-diagnosed and previously-treated follicular
lymphoma patients who were given rituximab induction
[60]. At the 10-year follow-up, the median event-free sur-
vival was 24 months for the rituximab maintenance arm,
compared with 13 months for the observation arm (p
<0.001) [28]. Multivariate Cox analysis indicated that pro-
longed rituximab treatment was the only favourable prog-
nostic factor, leading the authors to suggest that this main-
tenance regimen could be used regardless of other factors
including prior treatment, disease stage or Fc-receptor phe-
notype [28]. The findings from the SAKK 35/98 trial pro-
vide guidance on the rituximab dosing schedule for main-
tenance therapy (375 mg/m2 every 2 months) [60, 72].
Data from the PRIMA study supported the benefits of this
rituximab maintenance schedule for patients who achieve
remission after front-line therapy with several im-
munochemotherapy regimens [73]. The recent 6-year fol-
Figure 2: Algorithm for first-line treatment of follicular lymphoma.
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low-up results of the PRIMA study confirmed these earlier
findings [74]. With a median follow-up of 73 months,
6-year progression-free survival was 42.7% in the observa-
tion arm versus 59.2% in the rituximab maintenance arm,
(HR 0.58, 95% CI 0.48–0.69; p <0.0001). Preplanned sub-
group analyses showed that the effect of rituximab main-
tenance was consistent regardless of age, gender, FLIPI
score, induction regimen used and response to induction
treatment. There were no unexpected toxicities and the
6-year overall survival rate was similar in both study arms
(88.7% in the observation arm vs 87.4% in the mainte-
nance arm).
However, the duration of maintenance therapy is still a
matter of discussion. Recent results from the SAKK 35/03
trial provide clarification [75]. This study compared short-
term rituximab maintenance (one infusion every 2 months,
for a total of four administrations) with a long-term main-
tenance schedule (one infusion every 2 months for a max-
imum of 5 years, or until relapse, progression or unac-
ceptable toxicity) in 270 patients with untreated, relapsed,
stable, or chemotherapy-resistant follicular lymphoma who
had received rituximab induction monotherapy (375 mg/
m2). At a median follow-up of 6.4 years, the median event-
free survival was 3.4 years (95% CI 2.1–5.3 years) in the
short-term arm and 5.3 years (95% CI 3.5 years to not
available) in the long-term arm (p = 0.14). A sensitivi-
ty analysis focusing on late events showed a statistically
significant increase in event-free survival in favour of the
long-term maintenance regimen (7.4 years, 95% CI 5.1 to
not available compared with 3.5 years, 95% CI 2.1–5.9
years for the short-term arm; p = 0.04). Patients in the
long-term arm experienced significantly more adverse ef-
fects (p <0.001). No difference in overall survival between
the arms was seen. The primary endpoint from this trial
showed that long-term rituximab maintenance did not con-
fer a statistically significant benefit in terms of event-free
survival compared with the 8-month maintenance treat-
ment schedule.
In Switzerland, rituximab maintenance treatment is fre-
quently used even after a bendamustine-rituximab front-
line regimen. The current ESMO guidelines recommend
rituximab maintenance therapy according to the schedule
established in the PRIMA trial (rituximab 375 mg/m2
every 8 weeks for 2 years) [5].
Treatment of relapsed/refractory follicular
lymphoma
Nearly all patients will experience disease recurrence or
progression. There is no conclusive evidence to guide the
management of these patients and, in practice, choice of
therapy is driven by factors similar to those for first-line
treatment. Not all relapses necessitate immediate treat-
ment; asymptomatic cases may be managed with watchful
waiting until treatment is needed. When treatment is need-
ed, a variety of strategies are used. These include rechal-
lenge of the initial treatment regimen (when such treatment
has led to remission for more than a year), or use of a non-
crossresistant chemotherapy with or without rituximab.
Recently, highly effective immunochemotherapy regimens
with fewer toxic effects and the expanding array of new
agents have shifted the clinical focus away from stem cell
transplantation as a routine treatment option in relapsing
follicular lymphoma. However, none of the new agents
have demonstrated a potential for cure. Valuable time may
be lost with the use of palliative treatments during which
the time window for high-dose therapy may close for many
eligible patients. Accordingly, in patients fit enough to un-
dergo high-dose chemotherapy with autologous stem cell
transplantation, this approach should be strongly consid-
ered, especially for those with histologically transformed
disease. The curative potential of this approach was re-
cently demonstrated in a large retrospective analysis of
655 patients, with durable remissions irrespective of pre-
vious rituximab treatment [76]. Furthermore, patients who
experience early treatment failure after front-line im-
munochemotherapy may benefit from the use of autolo-
gous stem cell transplantation within ≤1 year of treatment
failure [77].
Radioimmunotherapy is an option for patients with low
tumour burden and minimal bone marrow involvement;
(90Y)-ibritumomab tiuxetan (Zevalin®) has been shown to
induce high response rates and durable remissions in re-
lapsed or refractory low-grade follicular lymphoma [78].
Interestingly, radioimmunotherapy given either as a single
agent or as consolidation after induction treatment has
been consistently shown to cure a certain fraction of pa-
tients with follicular lymphoma. Despite this fact, radioim-
munotherapy, although available in Switzerland, remains
rarely used. The concern over secondary cancers, the lack
of high-quality clinical studies and availability of the many
new agents may fuel the reluctance of many clinicians to
use this potentially curative treatment for follicular lym-
phoma.
In Switzerland, the majority of patients with relapsed or re-
sistant disease are treated with various immunochemother-
apy regimens. The ESMO guidelines define early relapses
as those occurring within 12 to 24 months of treatment [5].
In patients with early relapses, use of a non-cross-resistant
treatment regimen is recommended [5]. For patients who
relapse within 2 to 3 years of initial treatment, the same
first-line regimen may be used, unless the initial treat-
ment contained anthracyclines and retreatment would ex-
ceed the cumulative threshold of 450 mg/m2 doxorubicin.
Patients with a poor performance status and who showed
previous response to rituximab may benefit from rituximab
monotherapy [79]. For fit patients with symptomatic dis-
ease in need of treatment, several immunochemotherapy
regimens may be considered. The bendamustine-rituximab
regimen has been used successfully to treat patients with
relapsed/refractory follicular lymphoma following one to
two previous rituximab-based treatments, resulting in 95%
overall response and 80% complete response rates [80].
Fludarabine-based regimens are also often used for pa-
tients who relapse after alkylator-based therapies [15].
Nevertheless, bendamustine appears to have a better risk-
benefit profile than fludarabine in the relapse setting. The
StiL-2 study compared the use of bendamustine-rituximab
with fludarabine-rituximab in patients with relapsed or re-
fractory indolent NHL [81]. At a median follow-up of
96 months, median progression-free survival in the ben-
damustine-rituximab arm was 34.2 months versus 11.7
months in the fludarabine-rituximab arm (HR 0.54, 95%
CI 0.38–0.72; log-rank test p <0.0001) [81]. Of note, 11%
of the patients in the bendamustine-rituximab arm had pre-
viously received the same regimen as first-line treatment.
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Currently, there is no information comparing their re-
sponse with those who were bendamustine-rituximab
naïve. Fludarabine-based regimens are also known to have
adverse effects such as haematological toxicities and infec-
tions, precluding their use in the elderly or in those with
comorbidities [82].
In light of the ubiquitous application of rituximab in front-
line treatment regimens, the emergence of rituximab-resis-
tant disease is a problem [83]. The GADOLIN trial tested
the efficacy and safety of obinutuzumab plus bendamus-
tine against bendamustine alone in 413 patients who had
rituximab-refractory indolent NHL [84]. At a median fol-
low-up of 31.2 months, progression-free survival was sig-
nificantly longer with obinutuzumab-bendamustine (25.3
months) than with bendamustine monotherapy (14.0
months; p <0.0001). The latest update showed a significant
overall survival benefit in favour of obinutuzumab-ben-
damustine versus bendamustine alone (median not reached
vs 53.9 months; p = 0.0061) [85]. Swiss regulatory authori-
ties have recently approved obinutuzumab plus bendamus-
tine followed by obinutuzumab maintenance therapy for
follicular lymphoma patients who previously received a
rituximab-based therapy. Also approved and licensed in
Switzerland after failure of two prior treatments is idelal-
isib (Zydelig®), a phosphatidylinositol 3-kinase δ inhibitor
[86]. In a phase II open-label study of 125 patients with re-
lapsed or refractory indolent NHL, idelalisib monotherapy
showed antitumour activity and acceptable tolerability, in-
cluding in 72 patients with follicular lymphoma [87]. Sev-
eral ongoing trials are underway to evaluate idelalisib in
combination with rituximab or rituximab plus bendamus-
tine; however, some have been stopped owing to safety
concerns related to idelalisib. Another combination that
has shown efficacy in the relapse-refractory setting is
lenalidomide-rituximab (R2) [63]. Compared with
lenalidomide alone, the lenalidomide-rituximab regimen
showed a higher overall response rate (76 vs 53%) and
longer time to progression (2 vs 1.1 years), with no in-
creased toxicity [88]. The synergistic effects of this com-
bination warrant further investigation. Finally, the use of
low-dose involved-field radiation therapy remains a viable
option, particularly for patients with localised relapses. A
summary of the treatment of patients with relapsed/refrac-
tory follicular lymphoma is shown in figure 3.
Post-treatment assessment and patient follow-
up
The annual rate of histological transformation in follicular
lymphoma patients is around 3%, although this may be
slightly lower in the rituximab era [89]. A re-biopsy is
strongly recommended upon disease recurrence and before
initiating treatment of relapsed disease, to rule out the
presence of transformation to a higher-grade histological
subtype. The presence of histological transformation in
patients who responded to prior immunochemotherapy is
associated with poor outcomes and may warrant more ag-
gressive treatment [90]. PET-CT is widely used not only
for staging but also for assessment of interim response to
treatment and for evaluating response at the end of treat-
ment [91]. The presence of residual FDG-avidity at the end
of first-line treatment may be predictive of poorer clinical
Figure 3: Algorithm for the treatment of relapsed/refractory follicular lymphoma. SCT = stem cell transplantation.
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Table 3: Summary of the ESMO guidelines for the follow-up of patients with follicular lymphoma [5].
Examination Frequency
Medical history and physical examination After localised radiotherapy
Every 6 months for 2 years; thereafter once a year if needed
After systemic therapy
Every 3–4 months for 2 years; every 6 months for the following 3 years; thereafter once a year
Blood counts and routine chemistry tests Every 6 months for 2 years; thereafter as clinically indicated
Thyroid function After 1, 2 and 5 years in patients who received irradiation of the neck
Radiological or ultrasound tests Every 6 months for 2 years; thereafter once a year up to 5 years (optional)
PET-CT At mid-term and at the end of chemotherapy induction treatment.
We suggest that PET-CT is also used at diagnosis to identify areas for potential biopsy and to map fields
for localised radiation therapy.
CT = computed tomography; ESMO = European Society for Medical Oncology; PET = positron emission tomography
outcomes [92, 93], although it is still unclear how PET-
positivity should guide the choice of subsequent treatment.
The use of PET-CT is especially relevant in patients for
whom long progression-free survival is a treatment goal;
as such, PET-CT may not be necessary in older patients
or in those with significant comorbidities, whose treat-
ment goals are mainly symptomatic. There is evidence
that the hepatitis C virus (HCV) may be associated with
the development of B cell malignancies including follic-
ular lymphoma [94, 95], and that treatment of HCV may
be warranted prior to treatment of the lymphoma itself
[96, 97]. For patients who will receive R-CHOP or ben-
damustine-rituximab, antibiotic prophylaxis may be used
(sulphonamide/trimethoprim 960 mg 2–3 times per week,
or trimethoprim/sulfamethoxazole 160 mg/800 mg 3 times
per week).
There is still no conclusive evidence to support adherence
to a specific follow-up schedule. The latest ESMO guide-
lines provide a basis for the minimal follow-up in patients
with follicular lymphoma (table 3).
Conclusions
Much progress has been made towards achieving excellent
overall survival using immunochemotherapy, particularly
in those patients with limited-stage disease who respond
to anti-CD20 monoclonal antibody treatment. Indeed, the
slow course of the disease is at odds with the rapid pace at
which new treatments are being developed. The long fol-
low-up required for clinical trials means that some treat-
ment regimens are out of date before study closure [98].
For example, previous studies on rituximab maintenance
did not evaluate the efficacy of maintenance or salvage
regimens following front-line treatment with bendamus-
tine-rituximab, simply because this was not standard prac-
tice at the time of trial design [98]. Furthermore, it is still
difficult to extrapolate trial results to all follicular lym-
phoma patients, because of the heterogeneous nature of
the disease. The most urgent unmet need remains with
those patients whose disease is not responsive to anti-
CD20 treatment regimens and in whom minimal residual
disease persists even after immunochemotherapy, as well
as in those with early disease progression after first-line
treatment. For these patients, it will be essential to explore
the efficacy of novel agents and new combinations to
achieve prolonged remission and extended survival.
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